< Supplementary Information>

α-Aminophosphonates as novel antileishmanial chemotypes: synthesis, biological evaluation, and CoMFA studies

Srikant Bhagat^a, Parth Shah^a, Sanjeev K. Garg^a, Preet kamal^b, Sushma Singh^b and Asit K. Chakraborti^{a*}

^a Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar 160 062, PunJab, India ^b Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar 160 062, PunJab, India

Table of Contents

1.	Experimental Procedure about Biology	
2.	CoMFA Studies	
3.	Structures of the synthesized/screened compounds	
4.	General Information about Synthesis	
5.	Synthetic Procedure	S9
6.	Compound Characterizations	
7.	Scanned NMR spectral data of unknown compounds	S19
8.	References	

Corresponding Author

*Tel: 91-(0)-172 2214683. Fax: 91-(0)-172 2214692. E-mail: akchakraborti@niper.ac.in; akchakraborti@rediffmail.com.

1. Experimental Procedure about Biology

Screening Protocol

1.1. Chemicals

RPMI 1640 HEPES modified medium, antibiotics and DMSO was purchased from Sigma Chemicals Co. Foetal bovine serum (FBS) was purchased from Biological Industries. Absolute ethanol was supplied from Merck and had no effect on the morphology and proliferation of the renapromastigotes and macrophages.

1.2. Parasites and cell lines

Leishmania donovani wild type (WT, MHOM/80/IN/Dd8) promastigotes were cultured at 24°C in RPMI-1640, phenol red free medium supplemented with 0.2 % sodium bicarbonate, 100 µg/mL penicillin, 100 µg/mL streptomycin, 100 µg/mL gentamycin and 10 % heat inactivated foetal bovine serum and the pH of the medium was maintained at pH 7.2. The cells were washed in phosphate buffer saline (PBS) (pH 7.4) at 6000g for 10 mins at 24°C. The numbers of cells were counted on Neubauer hemocytometer. J774A.1 macrophages cell line was maintained in RPMI-1640 medium with 10% FBS (pH 7.2).

1.3. Antileishmanial assay / In vitro promastigote assay

Leishmanicidal activity of the compounds was investigated *in vitro* using MTT (Thiazolyl Blue Tetrazolium Bromide) assay¹ against *L. donovani* promastigotes. Exponentially growing cells were seeded to 96 well plate (*i.e.* $2x10^5$ cells /200 µL /well) and kept for growing at 24°C for 48 hours. Compounds were dissolved in absolute ethanol and the final concentration was maintained at 5% v/v. After 48 hours, different dilutions (10-100 µM) of each compound was prepared and added to wells in triplicates and further kept for incubation at 24°C for 48 hours. MTT was added to a final concentration of 400 µg/mL and further incubated at 37°C for 4 hours. The cells were centrifuged at 3000g for 10 minutes and the supernatant was removed. The resultant formazan formed was dissolved in 100 µL DMSO and absorbance was read at OD₅₄₀ nm on a microplate reader. The IC₅₀ values of the post treated viable cells were calculated relative to the untreated control cells and the results were expressed as the concentration of the compound inhibiting 50% of the parasite growth. Amphotericin B was used as the standard antileishmanial drug for data analysis

1.4. In vitro cytotoxicity assay

J774A.1 macrophage cell line was used for the *in vitro* cytotoxicity using MTT assay.¹ The cells were seeded on a 96 well tissue culture plate (*i.e.* 1×10^5 cells / 100 µL / well) and incubated at 37°C in humidified air with 5 % CO₂ for 24 hours. The cells were then exposed to the different dilutions of the drugs and kept for incubation for 48 hours at 37°C. The cells were centrifuged at 3000g for 10 minutes and the supernatant was removed without disturbing the cell layer. The resultant formazan was dissolved in 100 µL DMSO in each well and microplate was kept for shaking for proper mixing at 100 rpm. The final absorbance was read at OD₅₄₀ nm. The cytotoxicity was expressed as CC₅₀ *i.e.* 50 % reduction in the viability of the cells after treatment with the drugs in comparison to the controls.

2. CoMFA Studies

2.1 Data Set:

For 3D-QSAR analyses, 23 compounds with defined IC_{50} values were employed. Total compounds were divided into a training set of 18 compounds, and a test set of 5 compounds. The most important step in the QSAR is the selection of a suitable training set with wide activity range, responsible for determining the quality of the generated QSAR model. The calculated pIC_{50} values ($pIC_{50} = -logIC_{50}$) of dataset spanned across a small range from 4.04 to 5.15. These activity values were rescaled to the range of four log units to develop statistically reliable model. To rescale the activity data following formula was employed.² The test compounds were selected manually considering the structural diversity and wide range of activity in the data set.

Rescaling data set

Existing series = a-b, Rescale series = x-y, Rescale value =
$$x + (n-a)*[(y-x)/(b-a)]$$

$$=3.92+(n-4.04)*[3.6]$$

Where n is query. In our study, x= 3.92, y=7.92, a= 4.04, b= 5.15

2.2 Molecular modeling

All the molecular modeling calculations were performed using SYBYL 7.1 (Tripos Inc., USA) molecular modeling package installed on a Silicon Graphics Fuel Workstation running IRIX 6.5.³ Structures of all monophosphonate derivatives were generated using sketch molecule module. There are mainly two lower energy conformations of compound 1 (R and S). Energy comparison showed that S conformation was more stable than R conformation. To better understand the activities of these compounds both the conformations were used to build the model. Compound 1 being the most potent was selected as a template molecule. (Fig S1) Two different sets each of S and R configuration were individually evaluated. Geometry-optimized was carried out by applying Tripos molecular mechanics force field with conJugate gradient method. No constraints were applied on the internal geometries of the molecules. The minimization was terminated when the energy gradient convergence criterion of 0.001 kcal/mol was reached or when the 10,000 steps minimization cycle was exceeded. The fragment that was used as the common structure is shown in Fig. S2. Gasteiger- Hückel charges were applied to all the molecules of dataset, used for 3D-QSAR studies.

Figure S1. Confirmation of the template molecule compound 1



Figure S2. Common structure used during alignment of all monophosphonate derivatives



2.3 Molecular alignment for 3D-QSAR analysis

Molecular alignment is considered one of the most sensitive parameter in CoMFA analysis. Each molecule was aligned to the lowest energy conformation of the most active compound, **1**, by performing an rms fitting of the O-P-O backbone atoms of each conformer to those of the template using the alignment function of the Sybyl7.1. The aligned molecules obtained through pairwise superpositioning using the maximum common subgroup method, placed all molecules in the same reference frame as the reference compound shown in Fig. S3.





S- Conformation

R-Conformation

1.5.Calculation of CoMFA descriptors

For generating CoMFA contour maps, a 3D cubic lattice with grid spacing of 2.0 Å was created around aligned molecule. For CoMFA, the steric (The Lennard-Jones potential) and electrostatic (Coulombic potential) field at each lattice point was calculated using the default probe, a sp³ carbon atom with a charge of +1 and a van der Waals radius of 1.52 Å. The steric and electrostatic fields at these lattice points were calculated using Tripos force field. Energy values for these fields were truncated at 30 kcal/mol. The minimum column filtering was set to 2.5 kcal/mol to improve the signal-to noise ratio by retaining best fit model while omitting those lattice points whose energy variation was below this threshold. The optimal number of components in the final model was determined by using leave-one-out (LOO), a cross-validation method. The non-cross-validated conventional analysis was produced with the

optimal number of components equal to that yielding the highest r_{cv}^2 , Final model was evaluated based on the standard error of estimation values (SEE), non-cross validated r_{ncv}^2 value and also by the F test value.

The predictive abilities were determined from a test set of 5 compounds. pIC_{50} values for test molecules were predicted by using developed CoMFA. The predictive correlation coefficient (r_{pred}^2), based on the molecules of test set, was calculated according to the equation shown below;

$$r_{\text{pred}}^2 = \frac{(\text{SD} - \text{PRESS})}{(\text{SD})}$$

Where SD is the sum of squared deviations between the inhibitory activities of the test set and mean activities of the training molecules and PRESS is the sum of squared deviations between predicted and actual activity values for each molecule in the test set.



3. Chemical structure of training and test set molecules (Test Set *)

4. General Information about Synthesis

The glassware to be used in reactions was thoroughly washed and dried in an oven and the experiments were carried out with the required precautions. Chemicals and all solvents were commercially available (Aldrich Chemical, Merck AG, Fluka and S-D Fine Chemicals) and used without further purification/ drying unless otherwise mentioned. MaJority of the compounds are already reported in literature and the spectral characterization of these synthesized α -aminophosphonates are well comparable with them. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 300/400 MHz NMR spectrometer in CDCl₃ with residual undeuterated solvent (CDCl₃: 7.26/77.0) using TMS as an internal standard. Chemical shifts (δ) are given in ppm and *J* values are given in Hz. Splitting patterns were designated as s, singlet; bs, broad singlet; d, doublet; dd, doublet of doublet; t, triplet; m, multiplet. Evaporation of solvents was performed at reduced pressure, using a Büchi rotary evaporator. The isolated crude product was either recrystallized with ethanol or column purified using flash chromatography (Model: SP-1; Make: Biotage, Swedane)

Synthetic Procedure

General procedure for the synthesis of α -aminophosphonates in the absence of any catalyst: The mixture of the aldehyde (2.5 mmol), amine (2.5 mmol) and dimethylphosphite (3 mmol) was stirred magnetically under neat condition at room temperature for the required time mentioned (table 1). After the completion of the reaction (TLC), the reaction mixture was extracted with EtOAc (3 × 10 mL) and the combined EtOAc extracts were washed with water (2 × 10 mL) to remove any unreacted dimethylphosphite. The EtOAc extracts were dried (anh Na₂SO₄), filtered, and concentrated under rotary vacuum evaporation to afford the crude product which was further purified either by recrystallization with ethanol or column chromatography (20:80 EtOAc-Hexane).

General procedure for Mg(ClO₄)₂-catalysed synthesis of α -aminophosphonates (3, 4, 9, 11, 14 and 18): The mixture of the carbonyl compound (2.5 mmol) and anh Mg(ClO₄)₂ (5 mol %) was magnetically stirred with for 10-15 min followed by the addition of the amine (2.5 mmol) and dimethyl phosphite (3 mmol). The resultant mixture was stirred magnetically at room temperature or 80°C for the specified time till completion of the reaction (TLC). The mixture was diluted with water (2 mL) and extracted with EtOAc (3 × 10 mL). The combined EtOAc extracts were washed with water (2 × 10 mL) to remove any unreacted dimethylphosphite, dried (anh Na₂SO₄), filtered, and concentrated under rotary vacuum evaporation to afford the crude product which was further purified either by recrystallization with ethanol or column chromatography (20:80 EtOAc-Hexane).

5. Compound Characterizations

Compound code 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 19, 20, 21, 22, 23, 25 are already known molecules.

Spectral and physical property data:

[(4-Hydroxy-3-methoxy-phenyl)-phenyl amino-methyl]-phosphonic acid dimethyl ester, (table-1, entry 1)⁹:



Whitish yellow solid, Yield: 0.296 g, 88%; ¹H NMR (CDCl₃, 300 MHz) δ : 3.47 (3H, d, J = 10.49Hz), 3.74 (3H, d, J = 10.6Hz), 3.83(3H, s) 4.68 - 4.76 (1H, d, J = 23.8 Hz,), 6.60-7.26 (8H, m). HRMS (ESI) m/z calcd for C₁₆H₂₀NO₅PNa⁺ [M+Na]⁺, 360.0971; Observed: 360.0977. Column purified: 70:30 EtOAc: Hexane.

Dimethyl (4-hydroxyphenyl) (phenylamino) methylphosphonate, (table 1, entry 2)⁵:



Fade white solid; Yield: 0.265 gm, 86%; ¹H NMR (CDCl₃, 300 MHz) δ : 3.48 (3H, d, *J* = 10.5 Hz), 3.7 (3H, d, *J* = 10.6 Hz), 4.71- 4.79(1H, d, ¹*J*_{PH} = 24 Hz), 6.5-7.25 (9H, m). MS (Maldi) m/z 308(M+1)⁺, 198 [M⁺-P(O)(OMe)₂]. Column purified with 80:20 EtOAc: Hexane.

Dimethyl (4-methoxyphenyl)(5-methylisoxazol-3-ylamino)methylphosphonate, (table 1, entry 3):



White solid, Yield: 0.255 gm, 78%, **m.p: 153-154°C**; ¹H NMR (CDCl₃, 300 MHz) δ : 2.23(3H, S), 3.47(3H, d, J = 10.49 Hz), 3.78 and 3.80 (2S, 6H), 4.90-5.09 (1H, m, CH-P), 5.10 (1H, bs, -NH), 5.48 (1H, s), 6.86 (2H, d, J = 8.21 Hz), 7.40 (2H, d, J = 7.23 Hz); IR KBr) v: 1632 cm-1, 3434.7 cm-1; MS

(GCMS, EI) m/z $327(M+1)^+$, 217 [(M⁺-P(O)(OMe)₂]. HRMS (ESI) m/z calcd for C₁₄H₁₉N₂O₅PNa⁺ [M+Na]⁺, 349.0924; Observed: 349.0922; Column purified using (70:30) EtOAc: Hexane.

Dimethyl (4-methoxyphenyl) (4-methylbenzo[d] thiazol-2-ylamino) methyl phosphonate, (table 1, entry 4):



White solid, Yield: 0.291 gm, 76%, **m. p.: 85-86°C**; ¹H NMR (CDCl₃, 300 MHz) δ : 1.66 (1H, bs, NH), 2.54 (3H, s), 3.54(3H, d, J = 10.56 Hz), 3.77-3.81(6H, m), 5.30 (1H, d, J = 21.7 Hz), 6.88-7.49 (7H, m); IR (KBr) v: 1537.4 cm⁻¹, 3233.7 cm⁻¹; MS (MALDI) m/z 393.6(M+1)⁺, 283.5 [(M⁺-P(O)(OMe)_2]. HRMS (ESI) m/z calcd for C₁₈H₂₁N₂O₄PNa⁺ [M+Na]⁺, 415.0852; Observed: 415.0857.

Dimethyl (4-nitrophenyl) (phenylamino) methyl phosphonate, (table 1, entry 5)⁶:



Yellow solid, Yield: 0.271gm, 83%; ¹H NMR (CDCl₃, 400 MHz) δ : 3.60 (3H, d, *J*= 10.76 Hz), 3.78 (3H, d, *J* = 10.76 Hz), 4.80 (H, d, ¹*J*_{PH} = 25.4 Hz), 6.53-8.21 (9H, m); ¹³C NMR (CDCl₃, 100 MHz) δ : 53.87, 54.20, 54.81, 56.30 113.84, 126.59, 119.26, 123.91, 128.6, 129.4, 143.6, 145.3, 145.4, 147.6. MS (Maldi TOF TOF) m/z 337(M⁺), 227 [(M⁺-P(O)(OMe)₂].

Dimethyl (2-hydroxyphenyl) (phenylamino) methyl phosphonate, (table 1, entry 6)⁷:



Light green solid, Yield: 0.271 gm, 88 %; ¹H NMR (CDCl₃, 400 MHz) δ : 3.67 (3H, d, *J* =10.6 Hz), 3.74(3H, d, *J* =10.5 Hz), 5.98(1H, d, *J* =22.9 Hz), 6.66 - 8.80 (9H, m); ¹³C NMR (CDCl₃, 75 MHz) δ : 53.1, 53.8, 54.5, 114.5, 118.5, 119.6, 120.8, 121.2, 128.9, 129.3, 129.7, 145.9, 155.7; MS (Maldi) m/z 308 (M+1)⁺.

[(3-Hydroxy-4-methoxy-phenyl)-phenylamino-methyl]-phosphonic acid dimethyl ester, (table 1, entry 7)¹⁰:



Greenish white solid, Yield: 0.29 gm, 86 %; ¹H NMR (CDCl₃, 400 MHz) δ : 3.45(3H, d, J = 10.64 Hz), 3.74 (3H, d, J = 10.5 Hz), 3.85(3H, s) 4.67 (1H, d, ¹ $J_{PH} = 24.3$ Hz,), 6.58-7.11(8H, m); ¹³C NMR (CDCl₃, 100 MHz) δ : 55.83, 55.9, 54.3, 55.9, , 110.9, 113.9, 114.2, 118.5, 119.4, 128.4, 129.2, 145.9, 146.0, 146.2, 146.6; MS (Maldi) m/z 338(M+1)⁺. HRMS (ESI) m/z calcd for C₁₆H₂₀NO₅PNa⁺ [M+Na]⁺, 360.0971; Observed: 360.0978.

Dimethyl (phenyl-phenylaminomethyl) phosphonate, (table 1, entry 8)⁵:



Fade white Solid, Yield: 0.273gm, 94%; ¹H NMR (CDCl₃, 300 MHz) δ : 3.43 (3H, d, J = 10.9 Hz), 3.73 (3H, d, J = 12.7 Hz), 4.76-4.8 (2H, m), 6.58-7.47 (10H, m); ¹³C NMR (CDCl₃, 75 MHz) δ : 55.3, 55.4, 55.2, 57.2, 114.4, 119.1, 128.3, 128.6, 129.2, 129.7, 136.1, 146.5, 146.7; MS (APCI) m/z 291 (M)⁺, 182 [(M⁺-P(O)(OMe)_2].

(1-Phenyl-1-phenylamino-ethyl)-phosphonic acid dimethyl ester, (table 1, entry 9)⁴:



Fade yellow solid, Yield: 0.24 gm, 77 %; ¹H NMR (CDCl₃, 300 MHz) δ : 1.97 (3H, d, *J* = 16.5 Hz), 3.53-3.66(6H, m) , 6.38-7.81(10H, m); ¹³C NMR (CDCl₃, 75 MHz) δ : 20.84, 54.69, 117.28, 119.06, 128.07, 128.65, 128.96, 129.22; MS (APCI) m/z 305(M⁺), 196 [(M⁺-P(O)(OMe)₂].

[(4-Hydroxy-3, 5-dimethoxy-phenyl)- phenylamino-methyl]-phosphonic acid dimethyl ester, (table 1, entry 10)⁴:



Brownish yellow solid, Yield: 0.29 gm, 79 %; IR (KBr) v:1603 cm⁻¹, 2952 cm⁻¹, 3321 cm⁻¹, 3494.6 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ : 3.48 (3H, d, *J* = 10.56 Hz), 3.74 (3H, d, *J* = 10.64 Hz), 3.84(6H, s), 4.65-4.73(1H, d, ¹*J*_{PH} = 23.8 Hz), 6.60 - 7.14 (7H, m); ¹³C NMR (CDCl₃, 75 MHz) δ : 54.30, 54.52, 55.38, 56.90, 57.40, 105.02, 114.43, 119.15, 127.02, 129.73, 135.09, 146.67, 146.86, 147.85; MS (Maldi) m/z 367(M⁺), 257 [(M⁺-P(O)(OMe)₂].

(1-Phenylamino-cyclohexyl)-phosphonic acid dimethyl ester, (table 1, entry 11)⁴:



Fade yellow solid, yield: 0.26 gm, 91%; ¹H NMR (CDCl₃, 300 MHz)δ: 1.22-2.24 (10H,*m*), 3.65 (6H, *d*,*J*= 10.15), 6.78-7.2 (5H,*m*); ¹³C NMR (CDCl₃, 75 MHz) : 15.32, 15.47, 20.47, 25.78, 48.41, 48.52, 51.88, 54.01, 113.87, 114.96, 124.25, 141.13; MS (APCI) *m/z* 283 (M⁺), 174[(M + -P(O)(OMe)₂].

(3-Phenyl-1-phenylamino-allyl)-phosphonic acid dimethyl ester, (table 1, entry 12)⁵:



Yellowish brown solid, Yield: 0.28 gm, 87%; ¹H NMR (CDCl₃, 300 MHz) δ: 3.72-3.83 (6H, m,) 4.47-4.57 (1H, *dd*, *J*= 5.8 Hz, 25.46 Hz), 6.21-7.37(12H, m); ¹³C NMR (CDCl₃, 75 MHz) δ:52.96, 53.96, 54.58, 55.01,114.22, 118.91, 123.35, 127.04, 128.23, 128.98, 129.60, 133.65, 133.82, 136.56, 146.66, 146.82; MS (MALDI TOF TOF) *m/z* 317 (M⁺), 208 [(M⁺-P(O)(OMe)₂].



White solid, yield: 0.29 gm, 89%; ¹H NMR (CDCl₃, 400 MHz) δ: 3.41(3H, d, *J* = 10.5 Hz), 3.8 (3H, d, *J* = 10. 7), 3.94 (3H, s), 4.82 (1H, bs, NH), 5.4-5.5(1H, dd, *J* = 7.2 & 24.7 Hz), 6.6 -7.5 (9H, *m*); ¹³C NMR (CDCl₃, 100 MHz) : 46.8(<u>C</u>-P, d, *J*= 154 Hz), 53.67, 53.8, 55.9, 110.6, 113.6, 118.3, 112.1, 124.1, 128.2, 129.1, 146.0, 157.2; MS (APCI) *m*/*z* 321 (M⁺), 212 [(M⁺-P(O)(OMe)₂].

[(4-Chloro-benzothiazol-2-ylamino)-(4-methoxy-phenyl)-methyl]-phosphonic acid dimethyl ester, (table 1, entry 14)⁴:



Fade white solid, Yield: 0.32 gm, 77%; ¹H NMR (CDCl₃, 300 MHz) δ : 3.56(3H, d, *J* = 10.5 Hz), 3.75 (3H, s), 3.82(3H, d, *J* = 10.8 Hz), 5.50-5.57, 1H, d, *J*= 21.5 Hz), 6.85-6.97(3H, m), 7.25(1H, d, *J* = 7.7 Hz), 7.36 (1H, d, *J* = 7.7 Hz), 7.5-7.56(2H, m), 7.9 (1H, bs); ¹³C NMR (CDCl₃, 75 MHz) δ : 54.3, 54.7, 55.7, 56.4, 114.7, 119.7, 122.6, 124.3, 126.6, 127.1, 130.2, 132.9, 149.5, 160.2, 166.6; MS (MALDI) *m/z* 413(M⁺+1), 303 [(M⁺-P(O)(OMe)₂].

Dimethyl (2-bromophenyl) (phenylamino) methylphosphonate, (table 1, entry 15)¹¹:



Greenish white solid, Yield: 0.30 gm, 82%; ¹H NMR (CDCl₃, 400 MHz) δ : 3.4 (3H, d, J = 10.6 Hz), 3.8 (3H, d, J = 10.8 Hz), 5.0 (1H, bs, NH), 5.36 (1H, d, J = 24.6 Hz), 6.5-7.6 (9H, m); ¹³C NMR (CDCl₃, 100 MHz) : 53.2-54.7 (<u>C</u>-P, d, J = 152 Hz), 53.8, 53.9, 113.7, 118.7, 124.5, 124.6, 128.0, 129.1, 129.3, 129.6, 132.9, 135.3, 145.4, 145.6. HRMS (ESI) m/z calcd for C₁₅H₁₇BrNO₃P [M+Na]⁺, 392.0022; Observed: 392.0033.

Dimethyl (2-fluorophenyl) (phenylamino) methylphosphonate, (table 1, entry 16):



Light greenish blue solid, yield: 0.28 gm, 91%, **m. p.: 69-70°C;** ¹H NMR (CDCl₃, 400 MHz) δ : 3.5(3H, d, *J* = 10.6 Hz), 3.8 (3H, d, *J* = 10. 7), 5.2 (1H, d, *J* = 24.7 Hz), 6.6-7.5 (9H, *m*); ¹³C NMR (CDCl₃, 100 MHz) : 46.9(C-P, d, J= 155 Hz), 53.7, 54.0, 113.6, 115.2, 115.4, 118.8, 123.2, 123.3, 124.7, 128.8, 129.3, 129.7, 145.5, 145.7, 159.5, 161.9; MS (APCI) *m/z* 309 (M⁺), 200[(M⁺-P(O)(OMe)₂]. HRMS (ESI) m/z calcd for C₁₅H₁₇FNO₃PNa⁺ [M+Na⁺], 332.0822; Observed: 392.0827.

[(4-Methoxy-phenyl) –phenylamino -methyl]-phosphonic acid dimethyl ester, (table 1, entry 17)⁵:



Green solid, Yield: 0.29 gm, 91%; ¹H NMR (CDCl₃, 300 MHz) δ : 3.47-3.50 (3H, *d*, *J*= 10.5Hz), 3.73-3.77 (6H, 2s), 4.70-4.78 (1H, d, ¹*J*_{PH} = 23.88 Hz). 6.58-7.39 (9H, m); ¹³C NMR (CDCl₃, 75 MHz) δ : 54.31, 55.71, 56.52, 114.47, 114.74, 119.05, 127.87, 129.45, 129.73, 146.58, 146.78, 159.96; MS (EI) *m*/*z* 321 (M)⁺, 212[(M⁺-P(O)(OMe)₂].

Dimethyl(5-methylisoxazol-3-ylamino) (phenyl) methylphosphonate, (table 1, entry 18):



White solid: 0.23 gm, 76 %, **m. p.: 137-139°C;** ¹H NMR (CDCl₃, 300 MHz) δ : 2.24 (3H, S), 3.45 (3H, d, J = 10.54 Hz), 3.76 (3H, d, J = 10.7), 4.92-5.06 (2H, m), 5.5 (1H, s), 7.29-7.49 (5H, m); IR (KBr) v: 1626.9 cm⁻¹, 3273.1 cm⁻¹; MS (GCMS, EI) m/z 297(M⁺+1), 187 [(M⁺-P(O)(OMe)₂]. HRMS (ESI) m/z calcd for C₁₃H₁₇N₂O₄PNa⁺ [M + Na⁺], 319.0818; Observed: 319.0816.



Yellowish green solid, Yield: 0.30 gm, 92%; ¹H NMR (CDCl₃, 300 MHz) δ : 3.52 (3H, d, J = 10.63 Hz), 3.75 (3H, d, J = 10.79 Hz), 4.73-4.81 (1H, d, ¹ $J_{PH} = 24.51$ Hz), 6.45-7.43(9H, m); MS (Maldi TOF TOF) m/z 370(M⁺), 216 [(M⁺-P(O)(OMe)_2].

Dimethyl (4-bromophenyl) (phenylamino) methylphosphonate, (table 1, entry 20)⁸:



White solid, Yield: 0.31 gm, 81%, ¹H NMR (CDCl₃, 400 MHz) δ: 3.5(3H, d, *J* = 10.6 Hz), 3.7 (3H, d, *J* = 10.7 Hz), 4.7-4.8 (2H, m, merged proton with NH), 6.5-7.5 (9H, m); ¹³C NMR (CDCl₃, 100 MHz) : 53.8, 53.9, 54.5 (C-P, d, J= 150 Hz), 113.8, 118.8, 122.1, 129.3, 129.4, 129.5, 131.9, 134.8, 145.6, 145.8.

(Naphthalen-1-yl-phenylamino-methyl)-phosphonic acid dimethyl ester, (table 1, entry 21)⁴:



Light yellow solid, Yield: 0.28 gm, 83%; ¹H NMR (CDCl₃, 300 MHz) δ : 3.12(3H, d, *J*= 10.46Hz), 3.79(3H, *J*=10.75Hz), 5.62-5.70(1H, d, ¹*J*_{PH} = 24.091Hz), 5.62-8.23(12H, m); ¹³C NMR (CDCl₃, 75 MHz) δ : 50.13, 52.16, 53.78, 113.62, , 118.45, 122.58, 125.75, 126.51, 126.90, 127.71, 128.71, 129.11, 129.22, 131.40, 133.87, 145.83, 146.02; MS (APCI) *m*/*z* 341(M⁺), 232 [(M⁺-P(O)(OMe)₂].

(Phenylamino-pyridin-2-yl-methyl)-phosphonic acid dimethyl ester, (table 1, entry 22)⁵:



Fade brownish-white solid, Yield: 0.24 gm,81%; ¹H NMR (CDCl₃, 300 MHz) δ : 3.61(3H, *d*, *J* = 10.6 Hz), 3.76 (3H, *d*, *J* = 10.6 Hz), 4.98-5.07(1H, *dd*, *J* = 6.7Hz , 22.0 Hz), 5.2 (1H, s, NH) 3.83(3H, s) 6.68-7.68 (8H, m), 8.6(1H, *d*, *J* = 4.7 Hz); MS (APCI) *m/z* 292(M+1)⁺, 183 [(M⁺-P(O) (OMe)₂].

(Naphthalen-2-yl-phenylamino-methyl)-phosphonic acid dimethyl ester, (table 1, entry 23)⁴:



Yellowish green solid, Yield: 0.29 gm, 85 %; IR(KBr) v:1521.9 cm⁻¹, 1603.5 cm⁻¹, 2950 cm⁻¹, 3293.5 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz)\delta: 3.43(3H, d, J = 10.57 Hz), 3.74(3H, d, J = 10.67 Hz), 4.92-5.00(1H, d, ¹ $J_{PH} = 24.45$ Hz), 6.62-7.93 (12H, m) ; ¹³C NMR (CDCl₃, 75 MHz) δ : 55.81, 54.90, 56.90, 125.42, 125.47, 126.16, 126.25, 126.86, 126.96, 127.68, 128.01, 128.56, 129.20, 133.13, 133.26, 145.98, 146.18; MS (Maldi TOF TOF) m/z 341(M⁺), 232 [(M⁺-P(O)(OMe)₂].

Dimethyl cyclohexyl (phenylamino) methylphosphonate, (table 1, entry 24):



Fade white solid, Yield: 0.24 gm, 81 %, **m. p.:** 74-75°C; ¹H NMR (CDCl₃, 400 MHz) δ : 1.08-1.98 (10 H, m) 3.6(3H, d, *J* = 10.2 Hz), 3.7 (3H, d, *J* = 10.6 Hz), 3.84-3.88 (1H, m), 6.6-7.2 (5H, m); ¹³C NMR (CDCl₃, 100 MHz) : 25.9, 26.1, 26.3, 28.3, 30.8, 30.9, 39.8, 39.9, 52.3, 53.4, 55.1-56.6 (C-P, d, J= 150 Hz), 113.1, 117.9, 129.4, 147.5. HRMS (ESI) m/z calcd for C₁₅H₂₄NO₃P Na⁺ [M+Na]⁺, 320.1386; Observed: 320.1347.

[(4-Dimethylamino-phenyl)-phenylamino-methyl]-phosphonic acid dimethyl ester, (table 1, entry 25)⁵:



Yellowish orange solid, Yield: 0.31 gm, 93%; ¹H NMR (CDCl₃, 300 MHz) δ : 2.90 (6H, s) 3.45 (3H, d, J = 10.42 Hz), 3.72 (3H, d, J = 10.57 Hz), 4.66-4.74 (1H, d, ${}^{1}J_{PH} = 23.52$ Hz), 6.59-7.32(9H, m); MS (Maldi TOF TOF) m/z 336(M⁺+2), 225 [(M⁺ - P(O)(OMe)_2].

Dimethyl (3-hydroxyphenyl) (phenylamino) methylphosphonate, (table 1, entry 26):



Greenish-white solid, Yield: 0.25 gm, 82%, **m. p.: 120-121** °C; ¹H NMR (CDCl₃, 400 MHz) δ : 3.4 (3H, d, J = 10.6 Hz), 3.7 (3H, d, J = 10.7 Hz), 4.73 (1H, d, J = 24.2 Hz), 6.5-7.21(9H, m); ¹³C NMR (CDCl₃, 100 MHz): 54.0, 54.1, 54.7-56.3(C-P, d, J = 152 Hz), 113.9, 114.4, 115.8, 118.7, 119.7, 129.2, 129.9, 136.7, 145.9, 146.0, 157.3. HRMS (ESI) m/z calcd for C₁₅H₁₈NO₄P Na⁺ [M + Na⁺], 330.0866; Observed: 330.0874.

7. Scanned NMR spectral data of unknown compounds

7.1. ¹H NMR; Dimethyl (4-methoxyphenyl)(5-methylisoxazol-3-ylamino)methylphosphonate, (table 1, entry 3):



	649 974 4491 615 615 8156 5012 8330 0770 5012 8330 8330 8330 8330 8330 8330 8330 833	7552 0290	1382 9044 7849 8202 14680	54446	66490 25708 86204	06685 00126	Current Data Parameters NAME v-72 EXFNO 1 PROCNO 1
dd		5.3 5.3 5.3	3.6	5	1.	()	F2 - Acquisition Parameters Date20071107
		Y	AK			11	Time 10.33 INSTRUM dpx300
							PROBHD 5 mm GRP 14 PULPROG Zg30 32768
Me	P(O)(OMe) ₂		2				SOLVENT CDC13
IVIE			- P - 3				NS 10 DS 0
	N			1			FIDRES 0.228425 Hz
	CH ₃						AG 2.1889524 Sec RG 406.4
	*		100	100			DW 66.800 usec DE 6.00 usec
							TE 300.0 K
			11	-	. /		CLANNEL f1
				ſ			NUC1 1H
					6 7 3		P1 11.30 usec
							SF01 300.1324010 MHz
	1					1	F2 - Processing parameters
					×	1.1	SF 300.1300537 MHz
		1			1 6	1	NDW EM
	ALL UL	1			MIS		LB 0.30 Hz
	2W M	1			- Mala	l	- GB 0 PC 1.00
		111	1111	11	1111	11	1D NMR plot parameters
			0 0	8	53 88 81	05	CX 20.00 cm
gral	1794/ 1794/	190	386	.32		0.32	F1 3301.43 Hz
Inte	-000000	00		[==]			F2 -1.000 ppm F2 -300.13 Hz
	34 14 + 14 10		minipititi			minim	П РРМСМ 0.60000 ррл/с ИЗСМ 180.07803 Hz/сл
ppm 10	8	6	À		2	U	120N 20010100 111/0

7.2. ¹H NMR; Dimethyl (4-methoxyphenyl) (4-methylbenzo[d] thiazol-2-ylamino) methyl phosphonate, (table 1, entry 4):

7.3. ¹H NMR ; Dimethyl (2-fluorophenyl) (phenylamino) methylphosphonate, (table 1, entry 16):



¹³C NMR; Dimethyl(5-methylisoxazol-3-ylamino) (phenyl) methylphosphonate, (table 1, entry 16):



7.4 ¹H NMR; Dimethyl(5-methylisoxazol-3-ylamino) (phenyl) methylphosphonate, (table 1, entry 18):





7.5. ¹H NMR; Dimethyl cyclohexyl (phenylamino) methylphosphonate, (table 1, entry 24):

¹³C NMR; Dimethyl cyclohexyl (phenylamino) methylphosphonate, (table 1, entry 24):



S23



7.6. ¹H NMR; Dimethyl (3-hydroxyphenyl) (phenylamino) methylphosphonate, (table 1, entry 26):

¹³C NMR; Dimethyl (3-hydroxyphenyl) (phenylamino) methylphosphonate, (table 1, entry 26):



8. References:

- 1. T. Mosmann, J. Immunol. Methods 1983, 65, 55-63.
- M. Lalit, R. P. Gangwal, G. V. Dhoke, M. V. Damre, K. Khandelwal and A. T. Sangamwar, J. Mol. Struct. 2013, 1049, 315-325.
- 3. Cramer III, Richard D, EP19910913619, **1997**
- 4 S. Bhagat and A. K. Chakraborti, J. Org. Chem. 2008, 73, 6029-6032.
- 5. S. Bhagat and A. K. Chakraborti, J. Org. Chem. 2007, 72, 1263-1270
- 6. M. Tajbakhsh, A. Heydari, H. Alinezhad, M. Ghanei, S. Khaksar, Synthesis, 2008, 352-354.
- 7. Y. T. Reddy, P. N.Reddy, B. S. Kumar, P. Rajput, N. Sreenivasulu and B. Rajitha, *Phosphorus, Sulfur Silicon Relat. Elem.* **2007**, *182*, 161-65.
- 8. N. Azizi and M. R. Saidi., E. J. Org. Chem. 2003, 23, 4630-33.
- 9. B. Karmakar, S. Paul and J. Banerji, *ARKIVOC*, **2011**, 2, 161-71.
- 10. K. R. Reddy, K. S. Reddy, Ch. V. Reddy, M. Mahesh, P. V. K. Raju, and V. V. N. Reddy ,*Chem. Lett.*, **2005**, 34, 444-45.
- H. Hamadi, M. Kooti, M. Afshari, Z. Ghiasifar and N. Adibpour., *J. Mol. Catal. A: Chem.*, 2013, 373, 25-29.